Skip to content
IPIndiaPulseEquity intelligence
Sign inGet started
NIFTY 50
22,706.80
-104.55 (-0.46%)
NIFTY MIDCAP 100
57,210.55
-355.30 (-0.62%)
NIFTY BANK
54,942.50
-34.40 (-0.06%)
Dow Futures
52,686.50
-170.60 (-0.32%)
Indian market · As of 10:46 am IST
Results research

Concall Intelligence

Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.

Open reported results
Matching calls
2
After selected filters
Transcript verified
2
Official transcript summaries on this page
Preliminary briefs
0
Presentation evidence, clearly labelled
Processing
0
Transcript filed or call source found
Tracked companies
0
Watchlist or portfolio matches

Management evidence

Generated 22 Oct, 10:46 am IST · click a summary to inspect source-linked evidence for this results quarter.

Clear filters
CompanyCall and sourcesReported resultManagement outlookEvidence-led conclusionReview
MONOLITH
Monolithisch India Ltd.
Industrials · SME
Oct 2026
19 Oct 2026
Transcript verified
TranscriptRecording
Result pending
No matching current-quarter result row
Optimistic outlook
No comparable prior call
No measurable guidance

Monolithisch India Limited reported strategic progress centered on backward integration through the Nawada quartzite mine acquisition, which is expected to reduce raw material procurement costs by INR1,200 to INR1,400 per metric ton and lower inventory levels. Additionally, the company announced two new greenfield facilities in Western India (Udaipur) and Southern India (Hospet) with a combined capacity of 300,000 metric tons per annum and a total capex of INR45 crores, targe

Evidence summary ready
GRANULES
Granules India Limited
Pharma · Large
Sept 2026
6 Oct 2026
Transcript verified
TranscriptRecording
Result pending
No matching current-quarter result row
Optimistic outlook
No comparable prior call
No measurable guidance

Granules India Limited reported returning to growth in FY26 after three years of flat performance, backed by a strong net cash position following preferential warrants in September 2026. The company is executing a strategic transformation focusing on four growth engines (controlled substances, complex generics/early market opportunities, oncology, and peptide CDMO) while funding a 2,000 crore organic capex plan over the next 3 to 4 years.

Evidence summary ready
Method: Deterministic quarterly-result score from reported growth, margin direction and operating leverage. Derived only from extracted, source-linked management evidence. Pending is shown when evidence is insufficient. Measurable claims are separated from general commentary and retain outcome status when later evidence exists. Transcript-verified summaries rank above preliminary presentation briefs and source-only call evidence. Preliminary briefs are replaced automatically when an official transcript is processed. Management outlook and colours describe extracted commentary evidence; they are not buy or sell labels.